Neurothera Labs

CompanyUnited States

Neurothera Labs develops 2 assets, the furthest in phase 2 (palmitoylethanolamide in anxiety). Mostly small molecule acting on PPARA, inflammation and lipid and ceramide metabolism; based in the United States.

Assets
2
Furthest
Phase 2
Trials
1
Signals
0

Pipeline

2

  • palmitoylethanolamide

    Endogenous fatty acid amide acting via PPAR-alpha and endocannabinoid-related pathways to resolve inflammation and neuropathic pain.

    Phase 2Small moleculeLipid and ceramide metabolismPPARAanxietydiabetic peripheral neuropathy

  • THX-110

    Combination of dronabinol and palmitoylethanolamide targeting cannabinoid and PPAR-alpha pathways.

    Phase 2Small moleculePPARAInflammationtourette syndrome

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms4
  • Trials2
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 11 sources

Intelligence